Leinco Technologies is a leader in the development and manufacturing of antibodies and recombinant proteins for early discovery research and diagnostics. In response to the ongoing worldwide pandemic, Leinco Technologies offers an extensive line of SARS-CoV-2 antibodies and antigens at the highest functional purity levels you have come to know and trust. Leinco’s COVID-19 Neutralization MICRO-ELISA and COVID-19 IgG Serology Assay has completed Section IV.D notification process under FDA’s “Policy for Coronavirus Disease – 2019 Test During the Public Health Emergency (Revised)“ and has not been reviewed by FDA.

SARS-CoV-2 (COVID-19)